Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Malignant Glioma
Interventions: T2 (Observed)-Weighted Imaging, Biospecimen Collection, Magnetic Resonance Imaging; Procedure
Lead sponsor: John M. Buatti; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions: REGN7999, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia, Iron Deficiency
Interventions: Intrinsic Hepcidin IDx™ Test; Diagnostic Test
Lead sponsor: Intrinsic LifeSciences, LLC; Industry
Eligibility: 11 Years and older
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Exercise Performance
Interventions: Recombinant Bovine Lactoferrin, Bovine Milk-Derived Lactoferrin, Placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 42 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Term Infants Solely Formula Fed
Interventions: Enfamil LIPIL with iron, Good Start Supreme with DHA and ARA; Other
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 4 Days to 18 Days
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Rogers, Arkansas • Santa Ana, California + 14 more

Conditions: Anxiety, Stress, Memory Deficits, Cortisol Overproduction
Interventions: Heights Smart Supplement; Dietary Supplement
Lead sponsor: Heights; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Nervous System Diseases, Diagnostic Imaging
Interventions: Ferumoxytol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: End Stage Renal Disease
Interventions: Triferic, Heparin; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions: Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Blood Donation
Interventions: supplementation with low dose elemental iron; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 533 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anemia
Interventions: LY2787106, Iron Supplementation; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 6 more

Conditions: Restless Legs
Interventions: Ferric Carboxymaltose (FCM), Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Iron Deficiency Anemia
Interventions: Ferrous Sulfate; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Ligament Injury
Interventions: Oral Contraceptive Pill, norethindrn a-e estradiol-iron; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Iron Deficiency Anemia of Pregnancy
Interventions: Ferrous Sulfate; Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Glioblastoma
Interventions: Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging, Electronic Health Record Review, Ferumoxytol, Magnetic Resonance Imaging; Procedure · Other · Drug + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiomyopathy
Interventions: Sympathetic Nerve Activity, Mental Stress Test (Color Word Test), The Modified Oxford Technique for Baroreflex Sensitivity, Cold Pressor Test, Echocardiographic evaluation; Device · Behavioral · Drug + 1 more
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 21 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Anemia
Interventions: Oral iron tablets, VIT-45; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Female only
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions: blood donation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: nitroprusside, placebo infusion; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Little Rock, Arkansas • Stanford, California • Louisville, Kentucky + 4 more

Conditions: Kidney Failure, Chronic, Anemia, Iron-Deficiency
Interventions: iron sucrose injection, USP, sodium ferric gluconate complex in sucrose injection; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Phoenix, Arizona • Alhambra, California • Bell Gardens, California + 9 more

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions: SSP-004184AQ; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Oakland, California • Boston, Massachusetts

Conditions: Nutritional Deficiency
Interventions: Pearl millet, Biofortified pearl millet; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 36 Months
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Serum Hepcidin Immunoassay - Laboratory to Marketplace

Efficacy of Recombinant Bovine Lactoferrin (rbLf) in Iron Regulation

Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula

An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits

MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

BLOODSAFE Ghana- Iron and Nutritional Counselling Strategy

A Phase 1 Study of LY2787106 in Cancer and Anemia

Intravenous Iron Metabolism in Restless Legs Syndrome

Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia

Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes

Daily vs Intermittent Iron Therapy in Pregnancy

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

Iron Depletion Therapy for Type 2 DM and NAFLD

Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)

Comparison Between Effects of Two Iron Preparations on Protein in the Urine

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

Zinc and Iron Bioavailability From Biofortified Pearl Millet